Navigation Links
PharmaNet Development Group Experts to Share Insights at the 9th Annual Partnerships in Clinical Trials Conference in Vienna

PRINCETON, N.J., Nov. 1, 2010 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, today announced its experts will share their insights on key industry topics during the 9th Annual Partnerships in Clinical Trials Conference taking place from 16-19 November at Reed Messe in Vienna, Austria.  

At the conference, members of PharmaNet's management team will discuss the opportunities and challenges currently facing the CRO industry, including the impact of the economic environment on drug development and the need for innovative collaboration in post-marketing studies and biosimilar development.  

Wednesday 17 November 2010 Dalvir Gill, PhD, President, Late Stage Development, will give a keynote presentation, "Surviving Difficult Times: How Much Has the Recession Really Affected Clinical Outsourcing and How Does the Industry Need to Change?"

Jeff Trotter, Executive Vice President, Phase IV Development, will present "Successful Approaches to Partnering in Post-Marketing Studies."

Thursday 18 November 2010Dr. Pablo Fernandez, LMS, FFPM, Senior Vice President, Medical Affairs, will present "Partnering to Overcome the Challenges of Biosimilar Development."

Conference attendees can learn more about PharmaNet's capabilities by visiting booth 129 in the exhibition hall where an international team of representatives will be available to discuss PharmaNet's expertise in helping clients reach their goal of delivering safe and effective therapeutics to patients.

About PharmaNet Development Group, Inc.PharmaNet Development Group, a recognized leader of global drug development services to the pharmaceutical, biotechnology, generic drug, and medical device industries, provides comprehensive capabilities in Phase I-IV clinical development, bioanalytical and bioequivalence services, regulatory, staffing, and therapeutic solutions. For the applied knowledge and intelligent solutions needed to accelerate drug development programs of all sizes around the world, PharmaNet works for you. For more information, please visit Contact: Anne-Marie HessPhone:   (609) 951-6842E-mail:

SOURCE PharmaNet Development Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PharmaNet Development Group Appoints Anthony Maida, Vice President, Clinical Research
2. Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer
3. SEC Closes Investigation of PharmaNet Development Group and Recommends No Action
4. Christopher Brennan Joins PharmaNet Development Group as General Counsel
5. PharmaNet Development Group Provides Financial Update and Announces Geographic Expansion
6. PharmaNet Development Group Clinical Research Experts to Present at Global Professional Meetings in June
7. PharmaNet Development Group Gives Notice of Anticipated Fundamental Change and Merger to Holders of Its Convertible Notes
8. PharmaNet Development Group, Inc. Expands Latin America Operations with Opening of Brazil Office
9. An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share
10. PharmaNet Development Group Agrees to be Acquired by JLL Partners
11. Thrombosis Experts Present Update on Important New Developments in Anticoagulation Management
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
(Date:6/23/2016)... ... , ... In a new case report published today in STEM CELLS Translational ... lymphedema after being treated for breast cancer benefitted from an injection of stem cells ... this debilitating, frequent side effect of cancer treatment. , Lymphedema refers to ...
Breaking Biology Technology:
(Date:5/12/2016)... , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
Breaking Biology News(10 mins):